|Effect of novel modulators of protein kinase C activity upon chemotherapy-induced differentiation and apoptosis in myeloid leukemic cells.|
|PMID: 12187329 Owner: NLM Status: MEDLINE|
|Modulation of protein kinase C (PKC) activity has been demonstrated to either prevent or enhance drug-induced apoptosis in various tissue types. We tested four novel modulators of PKC activity in comparison to the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) for the capability to affect differentiation, cell cycle progression and apoptosis in the human myeloid leukemia cell lines U937 and HL-60. Farnesyl thiotriazole (FTT) and N-(n-heptyl)-5-chloro-1-naphthalenesulfonamide (SC-10) are both direct activators of PKC, whereas 6-(2-(4-[(4-fluorophe-nyl)phenylmethylene]-1-piperidinyl)ethyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one (R59022) and [3-[2-[4-(bis-(4-fluorophenyl)methylene]piperidin-1-yl)ethyl]-2,3-dihydro-2-thioxo-4(1H)-quin-azolinone (R59949) are diacyl glycerol kinase inhibitors that activate PKC by enhancing the levels of the endogenous ligand diacyl glycerol. U937 cells displayed a slight reduction in the number of cells in G(2)/M cell cycle phase after exposure to FTT, SC-10, R59022 and R59949, respectively. In contrast, HL-60 cells demonstrated a largely unaltered cell cycle distribution. Whereas TPA treatment resulted in a strong induction of p21(WAF/CIP1), c-Fos and c-Jun levels, neither one of the novel PKC activators altered expression of these proteins. Consequently, we tested the ability of the activators to cause membrane translocation of PKC. While TPA treatment resulted in translocation of the PKC isoforms alpha, delta and epsilon, SC-10 and FTT failed to induce alterations in the PKC content of the membrane and cytosolic fractions, respectively. Expression of the beta(2)-integrin CD11c that is induced during TPA-mediated differentiation remained unaltered after exposure to SC-10 and was partly reduced after treatment with FTT. To further investigate the effect of these activators upon apoptosis in leukemic cells, HL-60 and U937 cells were treated with 1-beta-D-arabinofuranosylcytosine (Ara-C) or etoposide (VP-16). Whereas TPA strongly reduced apoptosis in Ara-C- or VP-16-treated U937 cells, little if any reduction was observed after pretreatment with either FTT, SC-10, R59022 or R59949, respectively, in these cells. In contrast, TPA enhanced apoptosis in Ara-C- or VP-16-treated HL-60 cells. Interestingly, FTT and SC-10 demonstrated a protective effect in Ara-C-treated HL-60 cells. Taken together, these data suggest that the novel PKC activators FTT, SC-10, R59022 and R59949 exhibit modest biological effects upon leukemic blast cells, and are not capable of enhancing the apoptotic response of these cells to cytotoxic drugs.|
|Gerold Meinhardt; Elfriede Eppinger; Ralf Schmidmaier|
Related Documents :
|2411579 - Effects of a teratogen on [3h]uridine nucleotide transfer between human embryonal cells...
2165439 - Cytoskeletal dynamics in rabbit synovial fibroblasts: i. effects of acrylamide on inter...
3456469 - Cell differentiation and cell cycle effects on human promyelocytic leukemia cells induc...
2379149 - Differential effects of phorbol ester on epidermal growth factor receptors in estrogen ...
8652819 - Differential mechanisms targeting type 1 plasminogen activator inhibitor and vitronecti...
6261139 - Similarity of teleocidin b and phorbol ester tumour promoters in effects on membrane re...
15848769 - Cytotoxicities, cell cycle and caspase evaluations of 1,6-diaryl-3(z)-hexen-1,5-diynes,...
10574609 - Phosphorylcholine-containing polyurethanes for the control of protein adsorption and ce...
2246409 - Complete spontaneous regression of multiple basal cell carcinomas in the basal cell nev...
|Type: Journal Article|
|Title: Anti-cancer drugs Volume: 13 ISSN: 0959-4973 ISO Abbreviation: Anticancer Drugs Publication Date: 2002 Aug|
|Created Date: 2002-08-20 Completed Date: 2003-02-05 Revised Date: 2007-11-15|
Medline Journal Info:
|Nlm Unique ID: 9100823 Medline TA: Anticancer Drugs Country: England|
|Languages: eng Pagination: 725-33 Citation Subset: IM|
|Copyright 2002 Lippincott Williams & Wilkins.|
|Medizinische Klinik Innenstadt, Department of Hematology/Oncology, Ludwig-Maximilians-University, 80336 Munich, Germany. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Antigens, CD4 / biosynthesis
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects*
Cell Cycle / drug effects
Cell Differentiation / drug effects
Diacylglycerol Kinase / antagonists & inhibitors
Enzyme Activators / pharmacology*
Enzyme Inhibitors / pharmacology
Farnesol / analogs & derivatives*, pharmacology
Genes, fos / drug effects
Genes, jun / drug effects
Isoenzymes / antagonists & inhibitors
Leukemia, Myeloid / drug therapy, pathology*
Naphthalenes / pharmacology
Oncogene Protein p21(ras) / biosynthesis
Piperidines / pharmacology
Protein Kinase C / metabolism*
Pyrimidinones / pharmacology
Quinazolines / pharmacology
Sulfonamides / pharmacology
Thiazoles / pharmacology
Triazoles / pharmacology
Tumor Cells, Cultured
|0/Antigens, CD11c; 0/Antigens, CD4; 0/Antineoplastic Agents; 0/Enzyme Activators; 0/Enzyme Inhibitors; 0/Isoenzymes; 0/Naphthalenes; 0/Piperidines; 0/Pyrimidinones; 0/Quinazolines; 0/Quinazolinones; 0/Sulfonamides; 0/Thiazoles; 0/Triazoles; 102649-79-6/N-(m-heptyl)-5-chloro-1-naphthalenesulfonamide; 120166-69-0/R 59949; 156604-45-4/farnesylthiotriazole; 4602-84-0/Farnesol; 93076-89-2/R 59022; EC 220.127.116.11/Diacylglycerol Kinase; EC 18.104.22.168/Protein Kinase C; EC 22.214.171.124/Oncogene Protein p21(ras)|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multic...
Next Document: In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia.